The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000876392
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
3/03/2026
Date registered
Help: Date registered
16/07/2026
Date last updated
Help: Date last updated
16/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
16/07/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
A Study to Test the Safety and Effects of VIAL-IL13xTSLP in Healthy Adults
Scientific title
A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Proof-of-Mechanism of VIAL-IL13xTSLP in Healthy Adult Volunteers
Additional trial identifiers [1] 316665 0
None
Universal Trial Number (UTN)
U1111-1335-2078
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Asthma (Mild-to-moderate) 340902 0
Condition category
Condition code
Respiratory 337056 337056 0 0
Asthma

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Required 1a Cohorts: VIAL-IL13xTSLP administered as a single open-label, non-randomised intravenous infusion to healthy volunteers at five ascending dose levels (15, 50, 150, 400, and 800 mg); no placebo is administered.

Optional 1a Cohorts: VIAL-IL13xTSLP administered as a single open-label, non-randomised intravenous infusion to healthy volunteers at one additional dose level (between 800 and 1600 mg); and/or as a single open-label, non-randomised subcutaneous injection at up to two additional dose levels (up to 1600 mg); no placebo is administered. Initiation of optional cohorts is contingent upon Safety Review Committee approval following review of safety and tolerability data.

Adherence: Adherence is assured by on-site administration under direct medical supervision, with all participants followed for safety, pharmacokinetic, and pharmacodynamic assessments through Day 251 post-dose.
Intervention code [1] 333343 0
Treatment: Drugs
Description of the comparator or control
No control/comparators are administered in the open-label Healthy Adult Volunteer cohorts.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344565 0
Evaluate the safety and tolerability of VIAL-IL13xTSLP as a composite primary outcome.
Timepoint [1] 344565 0
— Adverse Events: Continuously from informed consent through Day 251. — Laboratory Tests: Screening, Days -1, 2, 3, 5, 8, 15, 29, 43, 57, 71, and monthly through Day 251. — Physical Examinations: Full examination at screening, Day 1, and Day 251; symptom-directed examination at Days -1, 2, 3, 5, 8, 15, 22, 29, 43, 57, 71, and 221. — Vital Signs: Screening, Days -1, 1, 2, 3, 5, 8, 15, 29, 43, 57, 71, and monthly through Day 251. — 12-lead ECGs: Screening, Days -1, 1, 2, 3, 5, 8, 15, 22, 29, 43, 57, 71, and monthly through Day 251.
Secondary outcome [1] 458350 0
Characterise the pharmacokinetics (PK) of VIAL-IL13xTSLP, including maximum observed plasma concentration (Cmax), time to maximum plasma concentration (Tmax), area under the plasma concentration-time curve (AUC), half-life (t½), mean residence time (MRT), systemic clearance (CL), and volume of distribution at steady state (Vss).
Timepoint [1] 458350 0
PK samples collected on Day 1 at pre-dose and at 1, 4, 6, 7 and 8 hours post-dose, then at Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 71, and monthly through Day 251.

Eligibility
Key inclusion criteria
All Participants:
- Body Mass Index (BMI) 18–32 kg/m²
- Considered healthy per investigator assessment
- Adequate contraception (females must use effective contraception, be postmenopausal, surgically sterile, or abstinent; males must use barrier contraception or be abstinent and refrain from sperm donation)
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
- Clinically significant medical history or concomitant medications
- Active/latent TB
- Malignancy within 5 years
- Autoimmune disorders
- HIV/HBV/HCV positivity
- Elevated liver/renal markers
- Eosinophilic disease
- Substance/alcohol use disorder
- Prior IL-13/TSLP biologics
- Live vaccine within 28 days.


Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 321278 0
Commercial sector/Industry
Name [1] 321278 0
Vial Australia Pty Ltd
Country [1] 321278 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Vial Australia Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 323991 0
None
Name [1] 323991 0
Address [1] 323991 0
Country [1] 323991 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319807 0
Bellberry Human Research Ethics Committee F
Ethics committee address [1] 319807 0
Ethics committee country [1] 319807 0
Australia
Date submitted for ethics approval [1] 319807 0
Approval date [1] 319807 0
02/02/2026
Ethics approval number [1] 319807 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148466 0
Dr Madhuchanda "Babil" Chatterjee
Address 148466 0
Vial Australia Pty Ltd, 428 George Street, WellShare, Level 7, Suite 12, Room 7, Dymocks Building, Sydney CBD, 2000
Country 148466 0
Australia
Phone 148466 0
+61 0474 485 209
Fax 148466 0
Email 148466 0
Contact person for public queries
Name 148467 0
Dr. Glenn Fitzpatrick
Address 148467 0
Vial Australia Pty Ltd, 428 George Street, WellShare, Level 7, Suite 12, Room 7, Dymocks Building, Sydney CBD, 2000
Country 148467 0
Australia
Phone 148467 0
+61 0474 485 209
Fax 148467 0
Email 148467 0
Contact person for scientific queries
Name 148468 0
Dr. Jared Sharp
Address 148468 0
Vial Health Technology, Inc., 1875 Mission Street Ste 103, #200, San Francisco, CA 94103
Country 148468 0
United States of America
Phone 148468 0
+1 415 300 0607
Fax 148468 0
Email 148468 0

Data sharing statement
Will the study consider sharing individual participant data?
No



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.